Xenon Pharmaceuticals Inc.
XENE· Nasdaq
XENEXenon Pharmaceuticals Inc.
Filed Mar 1, 2023 · 10-K · 60 days after period end · 0000950170-23-005582
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $3.74M | $5.15M | — |
| Net Income | -$37.40M | -$25.56M | -$12.32M | -$11.38M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 1, 2023 · 60 d after period end
